Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Roswell Park Comprehensive Cancer Center is pleased to announce the recent accreditation of its rectal cancer program by the National Accreditation Program for Rectal Cancer.

Roswell Park's National Cancer Institute-designated comprehensive cancer center will bring its expertise to the Capital Region.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Roswell Park-led study reveals benefits of combining adoptive cell therapy with immune checkpoint inhibitors in ovarian cancer.

A study led by Roswell Park researchers zeroes in on why some newly diagnosed glioblastoma patients survive longer than others after standard treatment plus SurVaxM.

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

Roswell Park Comprehensive Cancer Center endorsed a statement urging health care systems and professionals to choose HPV vaccination for cancer prevention.

Five new faculty members join network; three at St. Joseph’s Health in Syracuse as it launches new services.

Patients with lung cancer who take GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes management—fare better than those who don’t.

Findings reveal that cancer genomics similar to other populations, but with some distinctive features.

Findings suggest that treatment with an FGFR4 inhibitor can disrupt tumor spread in pancreatic cancer.

Health services company recognizes joint care offered through collaboration with Roswell Park Oishei Children’s Hospital.

Research shows that blocking CXCR2 receptor reduced tumor growth and improved survival; clinical trial underway.

Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies.

A New York cancer center appears on list for second consecutive year, based on anonymous employee surveys

Doctors join cancer center with expertise in surgical and medical oncology, pathology, dermatology, anesthesia.

Research centers across New York State are collaborating to develop cell therapies for cancer to expand progress in the emerging field of cell therapy.

Renier Brentjens, MD, PhD, invited to address Damon Runyon Foundation, New York Academy of Sciences

Roswell Park Comprehensive Cancer Center has been added to Newsweek’s list of America’s Best Cancer Hospitals for 2025.

Cancer center's Chief Strategy Officer and Chair of Thoracic Surgery joins prestigious organization

Experts from Roswell Park shared findings on these topics at the 2025 ASCO Annual Meeting.

Francisco J. Hernandez-Ilizaliturri, MD, discusses the design of an observational study investigating immunologic changes with venetoclax in CLL.

Matthew Cortese, MD, MPH, discusses the next steps for the multiomic evaluation of venetoclax activity in chronic lymphocytic leukemia.

Faculty from Roswell Park Comprehensive Cancer Center are among the experts invited to share their research findings at the 2025 ASCO Annual Meeting.

Collaborative Roswell Park/Columbia research uncovers greater risk of relapse and complications, lower survival rates.

The ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell agents in patients with solid tumors.

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.

Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues at the 2025 AACR Annual Meeting.